Clinical Trial Failures Risk: The success of XTL Biopharmaceuticals' drug candidates hinges on positive outcomes in clinical trials, and failure at any stage could halt development and diminish company value.

Regulatory Approval Uncertainty Risk: Even with positive trial data, XTL Biopharmaceuticals' experimental drugs require stringent regulatory approvals from health authorities, which are never guaranteed and can be lengthy and costly.

Significant Capital Requirements Risk: Developing new biopharmaceutical products is extremely capital-intensive, requiring XTL Biopharmaceuticals to raise substantial additional funds, which may not always be available on favorable terms or could dilute existing shareholders.